|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 prophylaxis (excluding childrens) meta-analysis
|ENSEMBLE (COV3001) unpublished|
|RCT||Janssen AD26 vaccine (JNJ-78436735)||placebo||COVID-19 prophylaxis (excluding childrens)||some concern||21895/21888||conclusif|
|6 studies excluded by filtering options (2 RCT / 4 OBS)|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).